Assay to detect IgM SARS-CoV-2 antibodies launch

Immunodiagnostic Systems Holdings plc.

9 October 2020

Launch of automated assay to detect IgM SARS-CoV-2 antibodies

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 13 August, our fully automated SARS-CoV-2 IgM antibody test ("the Test") will be available for sale from today.

The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centers and governmental bodies to ensure a roll-out according to national guidelines.

About the Test

· Detects specific IgM antibodies indicating recent exposure to the COVID-19 virus and that the immune system has started responding to the virus;

· When used in conjunction with IDS' automated SARS-CoV-2 IgG assay, will help laboratories to differentiate between the IgG and IgM antibody isotypes present in a sample;

· Test results available within 30 minutes.

All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 6111

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson